On February 9, 2026, bioAffinity Technologies, Inc. announced the appointment of Dr. David Ost, Dr. Daniel Sterman, and Dr. J. Scott Ferguson to its Medical and Scientific Advisory Board. This event is considered significant from an investor perspective due to the enhancement of leadership in their advisory capacity.